CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 9, 2005--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company focused primarily on products for the treatment of migraine, acute and chronic pain and other pain-related conditions, today announced the appointment of Elly Savaluny, Ph.D. as Vice President, Biostatistics and Data Management. Dr. Savaluny will be responsible for the data management and statistical analysis of clinical trials to support New Drug Application (NDA) submissions to the U.S. Food and Drug Administration (FDA) and submissions to other worldwide regulatory agencies.
